Alkermes Q1 2025 10-Q Filed
Ticker: ALKS · Form: 10-Q · Filed: 2025-05-01T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Alkermes Q1 2025 10-Q is in: Revenue from Vumerity & LYBALVI, assets & liabilities detailed.
AI Summary
Alkermes plc. filed a 10-Q for the period ending March 31, 2025. The filing details financial performance, including revenue from key products like Vumerity and LYBALVI. It also reports on assets such as buildings and certificates of deposit, and liabilities related to treasury stock.
Why It Matters
This filing provides investors with the latest financial snapshot of Alkermes plc., detailing revenue streams and asset/liability positions as of Q1 2025.
Risk Assessment
Risk Level: medium — The filing contains financial data that could indicate shifts in company performance, requiring careful analysis by investors.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of 2025 financial performance)
- 2025-03-31 — As of Date (End of the reporting period for financial statements)
Key Players & Entities
- Alkermes plc. (company) — Filer of the 10-Q
- Vumerity (product) — Product revenue
- LYBALVI (product) — Product revenue
- March 31, 2025 (date) — End of reporting period
- 20250331 (date) — Conformed period of report
FAQ
What were the key revenue drivers for Alkermes in Q1 2025?
The filing indicates revenue from products such as Vumerity and LYBALVI, as well as manufacturing revenue from other products and services.
What is the reporting period covered by this 10-Q filing?
The conformed period of report is March 31, 2025.
What types of assets are listed in the filing as of December 31, 2024?
The filing lists assets including buildings and improvements, and certificates of deposit.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What is the SEC file number for Alkermes plc.?
The SEC file number is 001-35299.
From the Filing
0000950170-25-061817.txt : 20250501 0000950170-25-061817.hdr.sgml : 20250501 20250501160529 ACCESSION NUMBER: 0000950170-25-061817 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250501 DATE AS OF CHANGE: 20250501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alkermes plc. CENTRAL INDEX KEY: 0001520262 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 981007018 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35299 FILM NUMBER: 25902988 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 BUSINESS PHONE: 00-353-1-772-8000 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: ANTLER SCIENCE TWO PLC DATE OF NAME CHANGE: 20110804 FORMER COMPANY: FORMER CONFORMED NAME: Antler Science Two Ltd DATE OF NAME CHANGE: 20110509 10-Q 1 alks-20250331.htm 10-Q 10-Q 0001520262 false --12-31 Q1 Alkermes plc. 56 0001520262 alks:ManufacturingRevenueMember alks:VumerityMember 2025-01-01 2025-03-31 0001520262 alks:LongActingINVEGAProductsMember us-gaap:RoyaltyMember 2025-01-01 2025-03-31 0001520262 2025-02-28 0001520262 us-gaap:BuildingAndBuildingImprovementsMember 2024-12-31 0001520262 alks:ManufacturingRevenueMember alks:VumerityMember 2024-01-01 2024-03-31 0001520262 alks:LYBALVIMember 2025-01-01 2025-03-31 0001520262 alks:OtherProductsAndServicesMember alks:ManufacturingRevenueMember 2024-01-01 2024-03-31 0001520262 us-gaap:CommonStockMember 2024-12-31 0001520262 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001520262 us-gaap:CertificatesOfDepositMember 2024-12-31 0001520262 alks:OtherProductsAndServicesMember us-gaap:RoyaltyMember 2024-01-01 2024-03-31 0001520262 alks:ProductReturnsMember 2025-01-01 2025-03-31 0001520262 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001520262 alks:OtherMember 2025-03-31 0001520262 us-gaap:RetainedEarningsMember 2025-03-31 0001520262 alks:ManufacturedProductAndRoyaltyMember 2024-01-01 2024-03-31 0001520262 alks:OtherAdjustmentsMember 2025-01-01 2025-03-31 0001520262 alks:MedicarePartDMember 2024-12-31 0001520262 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-03-31 0001520262 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001520262 us-gaap:CorporateDebtSecuritiesMember alks:LongTermInvestmentsMember 2025-03-31 0001520262 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001520262 alks:PerformanceBasedRestrictedStockUnitAwardsMember 2024-02-01 2024-02-29 0001520262 us-gaap:RoyaltyMember alks:VumerityMember 2025-01-01 2025-03-31 0001520262 us-gaap:RoyaltyMember 2024-01-01 2024-03-31 0001520262 alks:CraigHopkinsonMDMember 2025-03-14 2025-03-14 0001520262 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001520262 alks:RISPERDALCONSTAMember us-gaap:RoyaltyMember 2024-01-01 2024-03-31 0001520262 us-gaap:TreasuryStockCommonMember 2024-12-31 0001520262 2024-03-31 0001520262 us-gaap:OtherCurrentLiabilitiesMember 2024-12-31 0001520262 alks:ContractualAdjustmentsMember 2024-12-31 0001520262 alks:ShaneCookeMember 2025-02-27 0001520262 us-gaap:SegmentContinuingOperationsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2025-01-01 2025-03-31 0001520262 us-gaap:LandMember 2025-03-31 0001520262 2023-01-01 2023-01-31 0001520262 alks:ChristianToddNicholsMember 2025-03-10 0001520262 us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001520262 us-gaap:LeaseholdImprovementsMember 2025-03-31 0001520262 us-gaap:BuildingAndBuildingImprovementsMember 2025-03-31 0001520262 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0001520262 us-gaap:USGovernmentAgenciesDebtSecurit